临床试验中竞争风险的 primary efficacy 分析选择
针对二臂随机临床试验中带竞争风险的时间事件主要终点,研究比较了累积发生函数、Cox 模型及复合事件等分析策略。模拟显示累积发生函数不宜作主要疗效分析,而将竞争事件视为独立删失的 Cox 模型对 I 类错误和治疗效应偏倚控制较稳健;若存在强预后脆弱性,可考虑复合事件。
要点
- 累积发生函数可提供预后信息,但不建议作为主要疗效分析。
- 将竞争事件视为独立删失的 Cox 模型对 I 类错误和效应偏倚较稳健。
- 若存在强预后脆弱性,可考虑将主要与竞争事件合并为复合事件。
核心结论
- 累积发生函数不宜作为竞争风险下主要疗效分析,Cox 模型将竞争事件视为独立删失较稳健。
- 当存在强预后脆弱性时,可考虑将主要与竞争事件合并为复合事件进行分析。
研究设计与样本
- 针对二臂随机临床试验,模拟主要与竞争事件时间来自 cause-specific 和 joint subdistribution-cause-specific 风险模型。
- 扩展 Friedlin 和 Korn(2005)工作,同时考虑估计与检验。
- 以 Women's Health Initiative 临床试验数据示例分析。
主要发现
- 累积发生函数可提供特定患者的预后信息,但不建议用于主要疗效分析。
- 将竞争事件视为独立删失的 Cox 模型对 I 类错误和治疗效应偏倚控制较稳健,即使存在共享的中等预后未观测基线脆弱性。
- 当存在强预后脆弱性时,建议考虑复合事件。
- 对主要和竞争事件均有先验兴趣时,比较了双变量方法与复合事件方法。
临床怎么用
- 主要疗效分析优先采用将竞争事件视为独立删失的 Cox 模型。
- 若怀疑强预后脆弱性,可考虑复合事件作为主要分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigate different primary efficacy analysis approaches for a 2-armed randomized clinical trial when interest is focused on a time to event primary outcome that is subject to a competing risk. We extend the work of Friedlin and Korn (2005) by considering estimation as well as testing and by simulating the primary and competing events' times from both a cause-specific hazards model as well as a joint subdistribution-cause-specific hazards model. We show that the cumulative incidence function can provide useful prognostic information for a particular patient but is not advisable for the primary efficacy analysis. Instead, it is preferable to fit a Cox model for the primary event which treats the competing event as an independent censoring. This is reasonably robust for controlling type I error and treatment effect bias with respect to the true primary and competing events' cause-specific hazards model, even when there is a shared, moderately prognostic, unobserved baseline frailty for the primary and competing events in that model. However, when it is plausible that a strongly prognostic frailty exists, combining the primary and competing events into a composite event should be considered. Finally, when there is an a priori interest in having both the primary and competing events in the primary analysis, we compare a bivariate approach for establishing overall treatment efficacy to the composite event approach. The ideas are illustrated by analyzing the Women's Health Initiative clinical trials sponsored by the National Heart, Lung, and Blood Institute.
引用
- Troendle JF, Leifer ES, Kunz L, et al. Dealing with competing risks in clinical trials: How to choose the primary efficacy analysis? Stat Med. 2018. PMID: 29707832. doi:10.1002/sim.7800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。